VATS Lobectomy for Lung Cancer
Removing one segment instead of the whole lobe left twice as much local recurrence behind. Five year survival came out better anyway. Both findings are from one trial.
About This Department
Taking less lung left twice as much cancer behind in the chest. Five year survival came out better anyway.
JCOG0802 randomized 1,106 patients with clinical stage IA tumors of two centimeters or less between removing the whole lobe and removing one segment of it. Local relapse ran at 10.5 percent after segmentectomy and 5.4 percent after lobectomy. Five-year overall survival was 94.3 percent and 91.1 percent, favoring the smaller operation, and the trial met its threshold for superiority.
One phrase, two separate decisions
VATS lobectomy names two choices at once. Patients rarely get told they are separate. How the surgeon gets into the chest is one decision, and how much lung comes out is the other.
Conflating the two sends patients into the wrong argument. Reading that keyhole surgery is better teaches you nothing at all about whether you need a lobe removed or a segment of one, and being told you need a lobectomy teaches you nothing about how it will be done. They are different conversations with different evidence behind them.
Why the distinction matters at the consultation
Everything below separates them and then puts them back together.
The access question, and why it is settled
Keyhole lung surgery spread across the world for two decades on the strength of observational data, which is a weaker foundation than it sounds. Two randomized trials eventually tested it properly.
Drag the table sideways on a narrow screen.
| Trial | What it compared | What it found |
|---|---|---|
| 206 patients, Denmark, patients and assessors blinded | Four-port keyhole lobectomy against an anterolateral thoracotomy for stage I disease | Clinically meaningful pain in the first 24 hours affected 38 percent after keyhole surgery and 63 percent after thoracotomy. Episodes of moderate to severe pain stayed lower across a full year. Quality of life on one of the two instruments was better. |
| 503 patients, nine UK hospitals, blinded to discharge | One to four keyhole incisions without rib spreading against a single incision with rib spreading | Self-reported physical function at five weeks was better after keyhole surgery. Median hospital stay four days against five. Complications before discharge fell by roughly a quarter, while nodal upstaging, overall survival and progression-free survival were the same. |
What the two trials measured, and what they did not
The oncological result did not change and everything else did. That is what settled the question, and it is also why a surgeon offering an open operation now needs a specific reason for it.
Such reasons exist. A tumor invading the chest wall, a central tumor sitting on the pulmonary artery, dense scarring from previous infection or previous surgery, and the need for a sleeve resection all push toward opening the chest. None of those is a failure of technique. A surgeon who never opens a chest is patients instead of treating them.
How much lung comes out, and the finding that surprised the field
Lobectomy has been the standard operation for lung cancer since a trial in the 1990s found that smaller resections recurred more. That trial was small, it predated modern imaging, and it settled the question for thirty years. Two trials reopened it.
Two randomized trials reopened a question that a single small study had closed thirty years earlier, and they reopened it in the direction nobody expected.
The Japanese trial, which found superiority
JCOG0802 enrolled 1,106 patients at 70 institutions in Japan, all with clinical stage IA disease, tumors of two centimeters or less, and a consolidation-to-tumor ratio above 0.5 on thin-section CT, which is a way of saying the tumor was solid and not hazy. Randomization sent half to lobectomy and half to segmentectomy. At a median follow-up of 7.3 years, five-year overall survival came out at 94.3 percent after segmentectomy and 91.1 percent after lobectomy, with a hazard ratio of 0.663 that met the threshold for superiority and not merely for non-inferiority. Relapse-free survival landed at 88 percent in both arms. And local relapse ran at twice the rate after the smaller operation, 10.5 percent against 5.4 percent, and that difference reached statistical significance on its own, rather than appearing as noise. Three findings from a single trial, pulling in three different directions, and only one arrangement fits all three of them at once.
Those three findings only fit together one way. Segmentectomy left more disease behind in the chest and the patients still lived longer, because more of the lobectomy patients died of something other than lung cancer.
That was reported directly and not inferred. Of the deaths after lobectomy, 63 percent came from other diseases. After segmentectomy, 47 percent. Lung function at one year differed by 3.5 percent of predicted FEV1 in favor of segmentectomy, which the investigators had prespecified as below the level they would call clinically meaningful, so the mechanism is not simply that patients could breathe better afterwards. What the numbers describe is a population in which a smaller operation left people better able to survive the next twenty years of everything else that kills people in their seventies. Nobody predicted that shape of result, and it explains why this trial changed practice while its American counterpart merely confirmed safety. Competing mortality is an unglamorous phrase for the most consequential finding in early-stage lung surgery this decade, and it means something concrete for a patient sitting in a clinic. The lung you keep is doing work for the twenty years after the cancer is gone.
The American trial, which found non-inferiority
CALGB 140503 randomized 697 patients with tumors of two centimeters or less, after confirming during the operation that the hilar and mediastinal nodes were clear. Sublobar resection came out non-inferior to lobar resection for disease-free survival at a hazard ratio of 1.01, with five-year disease-free survival of 63.6 percent against 64.1 percent and five-year overall survival of 80.3 percent against 78.9 percent. Predicted FEV1 at six months favored the smaller operation by two percentage points. Recurrence patterns did not differ substantially. No signal pointed the other way.
Two trials, two designs, two different populations, and the same direction of travel. For a small solid tumor with clear nodes, the lobe is no longer automatically the answer.
Which operation fits which tumor
What pushes the decision one way or the other
Scroll the table sideways if your screen is narrow.
| Situation | Usual operation | Why |
|---|---|---|
| Solid tumor of two centimeters or less, peripheral, nodes clear | Segmentectomy is now a reasonable first choice | Two randomized trials support it, one finding better overall survival and one finding non-inferior disease-free survival |
| Tumor larger than two centimeters, or central | Lobectomy | Neither trial tested larger or central tumors, so the evidence for taking less does not reach them |
| Any involved lymph node found before or during surgery | Lobectomy with full nodal clearance | Both trials required node-negative disease. Nodal involvement changes the operation and usually adds treatment afterwards |
| Tumor crossing a fissure or filling more than one lobe | A larger resection, occasionally a pneumonectomy | Anatomy decides this and no technique changes it |
| Borderline lung function | Segmentectomy where the cancer allows, or radiation instead of surgery | Preserving lung tissue matters most in exactly the patients who have least of it to spare |
Look again at that last row, which connects to a separate decision. For a small peripheral tumor in someone who cannot have an operation at all, stereotactic radiotherapy is a genuine alternative with its own randomized evidence, and it belongs in the conversation before a borderline patient is pushed toward surgery they may not tolerate.
The lymph nodes, where a keyhole operation can quietly fall short
Removing the tumor is one job. The lymph node dissection is what tells you what stage the disease really is, and staging decides whether you need chemotherapy afterwards.
The theoretical risk, and what the trial found
Here the small-incision approach carries a real theoretical risk, because reaching the nodal stations through keyhole ports is harder than reaching them through an open chest. The VIOLET trial addressed it directly and found that upstaging from clinically node-negative to pathologically node-positive disease happened at the same rate in both arms, which is the measurement that matters, because a keyhole operation that missed positive nodes would show fewer of them. That reassurance is specific to an adequate dissection performed by a surgeon who does this regularly, and it is not a property of the instruments. The nodal stations do not become easier to reach because the incisions are small, so what the trial demonstrated is that experienced surgeons clear them just as well through ports, which is a different claim from saying the approach makes no difference to anyone who attempts it.
Get the node count. It ranks as the single most informative number in the whole operation report, and almost nobody requests it.
Robotic or thoracoscopic
Patients ask this constantly. What the evidence supports is narrower than the marketing.
A single-center randomized trial enrolled 320 patients between robotic-assisted and video-assisted lobectomy. Length of stay matched. So did complication rates. Neither arm had a perioperative death. Chest tube drainage ran higher in the robotic group. Hospitalization cost was substantially higher in the robotic group, by more than half again. The robotic group did harvest more lymph nodes, at a median of 11 against 10, more N1 nodes, and more nodal stations examined, and all three of those differences reached statistical significance.
How to read that
One extra lymph node at the median is a real difference and a small one, and whether it translates into better long-term outcomes is exactly what the trial could not answer, since it reported short-term results only. Both approaches use keyhole access and both avoid spreading the ribs, which is where the large benefit over open surgery comes from, so choosing between them on the platform means choosing on the weakest available evidence in the field. Choose instead on which operation your surgeon performs most weeks of the year. That is the strongest evidence available to any individual patient, it is easy to ask about, and it has the awkward property of being a question no brochure answers. Volume is not a proxy for skill and it is the best proxy available to a patient, which is an uncomfortable thing to write and a useful thing to know before choosing where to have a lobe removed.
One extra lymph node at the median, at substantially higher cost, with no measured difference in length of stay or in complications. That is the whole of the randomized evidence on this question.
Find out how many of your operation the surgeon performs in a year. That answer predicts your result better than the equipment does.
Whether you are fit for it
Lung cancer and poor lung function share a cause, so a large share of patients who need this operation are the patients least able to lose lung.
- Lung function testing. Spirometry for FEV1 and a gas transfer measurement for DLCO, both expressed as a percentage of predicted and then adjusted for how much lung the planned operation will remove.
- Exercise testing where the numbers are borderline. A stair climb, a shuttle walk or formal cardiopulmonary exercise testing, because measured performance beats a predicted figure.
- Cardiac assessment, since the risk factors for coronary disease and for lung cancer overlap almost completely.
- Smoking cessation, which reduces pulmonary complications and matters more when the operation gets brought forward than when it gets delayed.
- Prehabilitation where time allows. Two to four weeks of structured exercise before surgery improves measured fitness and is worth arranging when the schedule permits it.
What borderline numbers actually mean
Run the calculation for the operation you are actually being offered
Borderline numbers open a discussion about a smaller resection or about radiation, and they are not automatically a reason to refuse surgery. A predicted postoperative FEV1 that looks marginal for a lobectomy can look comfortable for a segmentectomy, which is one of the practical consequences of the trials above, and the calculation should be done for the specific operation being proposed and never for lobectomy in general.
The operation itself, and the possibility of converting
General anesthetic, a breathing tube that lets the anesthetist deflate the lung being operated on, and a catheter for the bladder. You will be positioned on your side.
The five steps inside the chest
- Two to four small incisions, usually between one and four centimeters, placed between the ribs without spreading them. A camera goes through one and instruments through the others.
- The pulmonary artery branch, the vein and the bronchus supplying the lobe or segment are each divided and sealed, most often with a surgical stapler.
- The specimen comes out through one of the incisions in a bag.
- The lymph node stations are sampled or cleared and labeled separately.
- One chest drain is placed through an existing incision, and the lung is reinflated under direct vision before closing.
Two to four hours covers most cases. Longer happens often and signals nothing bad.
Conversion to an open operation
Somewhere between a twentieth and a tenth of planned keyhole lobectomies become open operations, and the reasons are bleeding, dense adhesions, an unexpectedly central tumor, or an anatomical arrangement that cannot be handled safely through the ports. Consent for a keyhole operation is consent for this possibility, and a surgeon who converts when the operation demands it is exercising judgment rather than failing. The wrong incentive here is real, because a surgeon reporting a very low conversion rate is either unusually skilled, unusually selective in which patients they accept, or persisting through situations where they should have opened the chest, and only the first of those three counts as good news. Put the question to them directly. A surgeon comfortable with it will tell you their conversion rate and the reasons behind the last few cases, while a surgeon uncomfortable with it has answered you anyway, just not in words you were meant to hear.
The chest drain, the air leak, and the days in hospital
Most of what happens after a lobectomy comes down to one tube.
One drain removes air and fluid from the space where the lobe used to be, and lets the remaining lung expand to fill it. It comes out once the air leak has stopped and the fluid output has fallen, and everything in the recovery follows from that, including the day you go home. Everything.
Why the walking matters more than the resting
Nothing in that list is improved by lying still. Early walking is the single intervention with the clearest effect on pulmonary complications after lung surgery, and the days spent in a chair instead of a bed are the days that shorten the stay.
Breathing afterwards, and what actually recovers
A lobe accounts for a fifth to a third of one lung, depending which one. Patients expect to feel that loss permanently and most do not, which needs an explanation and not an assertion.
Remaining lung expands into the space while the diaphragm and chest wall adjust, so measured lung function at six to twelve months recovers past what a simple arithmetic subtraction would predict. The Japanese trial put the difference in predicted FEV1 at one year between removing a lobe and removing a segment at 3.5 percentage points, which the investigators had set out in advance as below the threshold they would call clinically meaningful. The American trial put the equivalent gap at six months at two percentage points, favoring the smaller operation in both cases and by a margin that neither set of investigators considered large enough to drive the decision on its own. What that leaves is a pair of trials agreeing that the breathing argument for a smaller resection is real and modest, and that the survival argument, where it exists, runs through something other than lung function alone. That is worth saying plainly, because patients are usually told the opposite.
What that means day to day
Pulmonary rehabilitation after surgery helps, and it is offered far less than it should be. Request a referral before you are discharged, since the programs that exist get volunteered to heart attack patients far more readily than they get volunteered to anyone who has just lost a lobe of lung.
What to be skeptical of
And one that runs the other way
One more that runs the other way. Be wary of anyone treating a lobectomy as a minor procedure because the incisions are small, since the operation inside the chest is identical and the recovery is measured in months.
Having the operation away from home
Lung surgery travels better than most cancer treatment, because it is one admission instead of a course, and it travels badly in one specific way.
How long you need to be here
Reckon on two to three days of assessment before the operation, four to seven days in hospital afterwards for most patients, and a further week to ten days locally before flying. That puts a realistic stay at around two and a half to three weeks. A prolonged air leak is the thing that extends it, so the return flight should be bookable and not booked, and the accommodation should be arranged for longer than the expected stay. The specific way this travels badly is that the pathology report arrives after you have flown home, and the pathology is what decides whether you need chemotherapy, so the arrangement for that conversation has to exist before you leave. Decide who reads the pathology with you and how they reach you, and write it down before the operation rather than after it, because a report that arrives by email with nobody attached to explain it is how an adjuvant chemotherapy decision gets postponed by a month.
Follow-up once you are back home
Once you are back home the handover is what carries you. The operation report naming which lobe or segment was removed and which nodal stations were examined, the full pathology report with the node count and the pathological stage, the discharge x-ray, and a written statement of whether adjuvant treatment is recommended and on what timetable. Anyone following you at home needs all four once you are back home. The adjuvant question is the one that goes wrong when a patient flies home before the pathology is final. Surveillance scanning then runs for years on a schedule that should be written down before you leave.
How a quotation for this operation is built
No prices appear on this page. Nobody can put a figure on an operation before reading the scans and the lung function tests, so what follows sets out the anatomy of a quotation line by line.
Swipe the table sideways on a small screen.
| Line on the quotation | What sits behind it |
|---|---|
| The operation | Surgeon, anesthetist, theater time and the staplers and sealing devices, which in this operation are a real consumable cost rather than a rounding error. |
| The platform | Robotic assistance costs considerably more than thoracoscopic instruments and performed comparably in the one randomized comparison, so this line deserves a question. |
| Intensive care or high-dependency time | Usually one night, sometimes none, occasionally several. Quotations differ on whether this is included or itemized. |
| Length of stay | Four to seven days in the common case, longer with a prolonged air leak, and this is the line most likely to move after the fact. |
| Pathology and staging | Examination of the specimen and every nodal station, which is what produces the stage that decides the next step. |
| Imaging and assessment before and after | PET-CT, lung function testing, cardiac assessment and the discharge films. |
Six lines, and the one to check before any of them
What a quotation leaves out
Establish what happens to the figure if the stay runs long or the operation converts to open, because a quotation built on the uncomplicated course and silent on the alternative has not answered the question that matters. Prolonged air leaks are common. Ask.
VATS lobectomy FAQ
Is keyhole surgery as good as open surgery for the cancer itself?
Yes, on the evidence available. In the 503-patient UK trial, nodal upstaging, overall survival and progression-free survival were the same in both arms, while pain, complications and length of stay all favored keyhole access. The oncological result was the thing the trial was designed not to compromise, and it did not.
Should I ask for a segmentectomy instead of a lobectomy?
A fair question for a solid peripheral tumor of two centimeters or less with clear lymph nodes, where the evidence now runs strong, and a question the trials cannot answer outside that description, which leaves your scan and your nodes to decide it. Bring it to the consultation. Expect a specific answer.
How much of my breathing will I lose?
Less than the arithmetic suggests. Measured lung function at six to twelve months recovers well beyond a simple subtraction, because the remaining lung expands into the space. In the Japanese trial the Japanese trial put the difference in predicted FEV1 at one year between removing a lobe and a segment at 3.5 percentage points, below the level the investigators called clinically meaningful. Someone with normal lung function beforehand returns to normal activity in most cases.
How long will I be in hospital?
Four days, as the median in the UK trial after keyhole lobectomy, against five after open surgery, with the chest drain deciding it and a prolonged air leak the usual reason a stay runs to a week or beyond. Some leave on day two.
Is the robot better?
Not on the evidence. In a 320-patient randomized trial, length of stay and complications were comparable, cost ran substantially higher for the robot, and the robotic group harvested one more lymph node at the median. Both use keyhole access. How many of these operations your surgeon performs matters more than which instruments they hold.
Will I need chemotherapy afterwards?
The pathology decides that and the operation does not. Stage comes from the specimen and the lymph nodes, so the answer arrives a week or two after surgery, which means anyone traveling for this operation needs to arrange in advance who will have that conversation and where it will happen.
What if the keyhole operation has to become an open one?
It happens in somewhere between one in twenty and one in ten planned cases, for bleeding, scarring or anatomy, and it is a judgment call made to keep you safe. Consent covers it. Establish what the surgeon does in that situation, and what it means for your recovery is a longer stay and more pain, with no penalty at all to the cancer outcome.
References
- Saji H, Okada M, Tsuboi M, Nakajima R, Suzuki K, Aokage K, et al. Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L). A multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial. Lancet. 2022;399(10335):1607-1617.
- Altorki N, Wang X, Kozono D, Watt C, Landrenau R, Wigle D, et al. Lobar or sublobar resection for peripheral stage IA non-small-cell lung cancer. New England Journal of Medicine. 2023;388(6):489-498.
- Lim E, Harris RA, McKeon HE, Batchelor TJP, Dunning J, Shackcloth M, et al. Impact of video-assisted thoracoscopic lobectomy versus open lobectomy for lung cancer on recovery assessed using self-reported physical function. VIOLET RCT. Health Technology Assessment. 2022;26(48):1-162.
- Bendixen M, Jørgensen OD, Kronborg C, Andersen C, Licht PB. Postoperative pain and quality of life after lobectomy via video-assisted thoracoscopic surgery or anterolateral thoracotomy for early stage lung cancer. A randomised controlled trial. Lancet Oncology. 2016;17(6):836-844.
- Jin R, Zheng Y, Yuan Y, Han D, Cao Y, Zhang Y, et al. Robotic-assisted versus video-assisted thoracoscopic lobectomy. Short-term results of a randomized clinical trial (RVlob trial). Annals of Surgery. 2022;275(2):295-302.
Editor's note
Written by the Biruni Hospital medical editorial team. Reviewed by Assoc. Prof. Dr. Uğur Temel, Thoracic Surgery.
Medically reviewed by
Assoc. Prof. Dr. Uğur Temel
Thoracic Surgery
Related Treatments
View All
EBUS Guided Biopsy - Endobronchial Ultrasound Biopsy
A PET scan cannot tell a lymph node inflamed by smoking from one that holds cancer, and the difference decides whether a lung cancer is operated on. EBUS settles it with a needle through the airway wall, under sedation, with no incision. Read what the trials found, what a negative result means, and how to plan three nights or a week in Istanbul.
Lobectomy - Lung Lobe Removal Surgery
A lobectomy removes one lobe of the lung with its lymph nodes and is the standard operation for early lung cancer, done through small keyhole incisions for most patients with three to five nights in hospital. This page explains who needs one and when a smaller segmentectomy is enough, how keyhole, robotic and open approaches compare, the operation and recovery week by week, the risks, what three randomized trials show, and how patients from abroad arrange it in Istanbul.
Pulmonary Metastasectomy - Lung Metastasis Surgery
Cancer that has spread to the lungs can sometimes be removed through keyhole incisions, a wedge at a time. Four conditions decide who gains, and the largest registry puts five-year survival after complete removal at 36 percent. The one randomized trial, in bowel cancer, found that carefully chosen patients who were watched instead lived nearly as long, and a page that hides that is not worth reading.
VATS Surgery - Video-Assisted Thoracoscopic Surgery
Nothing inside the chest is done differently. The lobe, the lymph nodes and the pathology are the same as in open surgery, and two blinded randomized trials measured what avoiding rib spreading is worth in pain, complications and days in hospital. Read who is a candidate, what the stay involves and when it is safe to fly home.